Xencor Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Xencor Inc 公司

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Xencor Inc簡介



公司代碼XNCR

公司名稱Xencor Inc

上市日期Dec 03, 2013

CEODahiyat (Bassil I)

員工數量250

證券類型Ordinary Share

年結日Dec 03

公司地址465 N. Halstead St.

城市PASADENA

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編91107

電話16263055900

網址https://xencor.com/

公司代碼XNCR

上市日期Dec 03, 2013

CEODahiyat (Bassil I)

Xencor Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. John R. Desjarlais, Ph.D.

Executive Vice President - Research, Chief Scientific Officer

224.60K

+5322.00%

Ms. Celia E. Eckert

Senior Vice President, General Counsel, Corporate Secretary

50.68K

+16209.00%

Mr. Bart Jan Cornelissen

Senior Vice President, Chief Financial Officer

33.17K

-3750.00%

Mr. Kurt A. Gustafson

Independent Director

14.20K

+10693.00%

Mr. Todd E. Simpson

Independent Director

13.69K

+13686.00%

Mr. Richard J. (Rich) Ranieri

Independent Director

13.20K

+10693.00%

Dr. Bassil I. Dahiyat, Ph.D.

President, Chief Executive Officer, Founder and Director

--

Dr. A. Bruce Montgomery, M.D.

Lead Independent Director

--

Dr. Kevin C. Gorman, Ph.D.

Independent Director

--

Dr. Ellen Gwen Feigal, M.D.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. John R. Desjarlais, Ph.D.

Executive Vice President - Research, Chief Scientific Officer

224.60K

+5322.00%

Ms. Celia E. Eckert

Senior Vice President, General Counsel, Corporate Secretary

50.68K

+16209.00%

Mr. Bart Jan Cornelissen

Senior Vice President, Chief Financial Officer

33.17K

-3750.00%

Mr. Kurt A. Gustafson

Independent Director

14.20K

+10693.00%

Mr. Todd E. Simpson

Independent Director

13.69K

+13686.00%

Mr. Richard J. (Rich) Ranieri

Independent Director

13.20K

+10693.00%

收入明細

單位: USD更新時間: 1月6日週二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Royalties

21.00M

0.00%

Milestone

0.00

0.00%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Royalties

21.00M

0.00%

Milestone

0.00

0.00%

股東統計

更新時間: 5 小時前

持股股東

股東類型

持股股東

佔比

PRIMECAP Management Company

14.95%

BlackRock Institutional Trust Company, N.A.

14.82%

The Vanguard Group, Inc.

10.01%

RTW Investments L.P.

8.71%

EcoR1 Capital, LLC

8.60%

其他

42.90%

持股股東

佔比

PRIMECAP Management Company

14.95%

BlackRock Institutional Trust Company, N.A.

14.82%

The Vanguard Group, Inc.

10.01%

RTW Investments L.P.

8.71%

EcoR1 Capital, LLC

8.60%

其他

42.90%

股東類型

持股股東

佔比

Investment Advisor

56.73%

Investment Advisor/Hedge Fund

36.45%

Hedge Fund

18.64%

Research Firm

4.71%

Individual Investor

1.34%

Venture Capital

1.05%

Pension Fund

0.91%

Bank and Trust

0.36%

Sovereign Wealth Fund

0.08%

機構持股



更新時間: 1月21日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q4

364

84.79M

119.03%

--

2025Q4

446

84.30M

118.05%

-5.40M

2025Q3

434

80.43M

112.65%

-6.04M

2025Q2

437

81.68M

114.52%

-1.81M

2025Q1

459

80.70M

113.40%

-3.00M

2024Q4

454

76.54M

108.64%

-2.55M

2024Q3

455

73.66M

105.55%

+3.66M

2024Q2

436

65.64M

106.20%

-4.06M

2024Q1

431

66.91M

108.52%

-498.74K

2023Q4

420

65.39M

107.20%

-1.62M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

PRIMECAP Management Company

10.68M

14.95%

+147.70K

+1.40%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

10.58M

14.82%

-92.56K

-0.87%

Sep 30, 2025

The Vanguard Group, Inc.

7.17M

10.04%

+80.65K

+1.14%

Nov 28, 2025

RTW Investments L.P.

6.22M

8.71%

+3.82M

+158.90%

Sep 30, 2025

EcoR1 Capital, LLC

6.14M

8.6%

--

Sep 30, 2025

BVF Partners L.P.

4.62M

6.47%

+1.88M

+68.58%

Oct 17, 2025

State Street Investment Management (US)

3.67M

5.14%

-143.78K

-3.77%

Sep 30, 2025

TCG Crossover Management, LLC

2.45M

3.43%

--

Sep 30, 2025

Geode Capital Management, L.L.C.

1.73M

2.42%

+25.16K

+1.48%

Sep 30, 2025

Dimensional Fund Advisors, L.P.

1.59M

2.23%

-191.61K

-10.76%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Genomics Immunology and Healthcare ETF

2.09%

Tema Oncology ETF

1.16%

Virtus LifeSci Biotech Clinical Trials ETF

1.06%

Invesco NASDAQ Future Gen 200 ETF

0.97%

Invesco S&P SmallCap Health Care ETF

0.64%

ALPS Medical Breakthroughs ETF

0.43%

State Street SPDR S&P Biotech ETF

0.33%

Inspire Small/Mid Cap ESG ETF

0.3%

Direxion Daily S&P Biotech Bull 3X Shares

0.15%

ProShares Ultra Nasdaq Biotechnology

0.15%

iShares Genomics Immunology and Healthcare ETF

佔比2.09%

Tema Oncology ETF

佔比1.16%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.06%

Invesco NASDAQ Future Gen 200 ETF

佔比0.97%

Invesco S&P SmallCap Health Care ETF

佔比0.64%

ALPS Medical Breakthroughs ETF

佔比0.43%

State Street SPDR S&P Biotech ETF

佔比0.33%

Inspire Small/Mid Cap ESG ETF

佔比0.3%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.15%

ProShares Ultra Nasdaq Biotechnology

佔比0.15%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據